Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07456059 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults
A Phase 1 study, sponsored by Edgewise Therapeutics.
- Not yet
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07456059 is a Phase 1 study that has not yet begun recruiting, run by Edgewise Therapeutics. The registered enrollment target is 24 participants.
The verdict
NCT07456059, a Phase 1 study, has not yet begun recruiting, sponsored by Edgewise Therapeutics.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after single and multiple doses in Japanese and Caucasian adults. The safety of EDG-7500 in these adult participants will also be evaluated in this study.
Interventions
- DRUG EDG-7500
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-03 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07456059
The ClinicalTrials.gov registry entry for NCT07456059 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edgewise Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EDG-7500 is the first listed.
NCT07456059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07456059 about?
NCT07456059 is a clinical study titled "A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults". The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after single and multiple doses in Japanese and Caucasian adults. The safety of EDG-7500 in these adult participants will also be evaluated in this study.
What is the current status of trial NCT07456059?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-03. Estimated completion is 2026-06.
What interventions are being tested in trial NCT07456059?
The interventions under investigation include: EDG-7500 (DRUG).
Who is sponsoring clinical trial NCT07456059?
This trial is sponsored by Edgewise Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.